Effect of granulocyte-colony stimulating factor on expression of selected proteins involved in regulation of apoptosis in the brain of newborn piglets after cardiopulmonary bypass and deep hypothermic circulatory arrest  by Pastuszko, Peter et al.
Evolving Technology/Basic Science Pastuszko et al
E
T
/B
SEffect of granulocyte-colony stimulating factor on expression of
selected proteins involved in regulation of apoptosis in the brain of
newborn piglets after cardiopulmonary bypass and deep hypothermic
circulatory arrestPeter Pastuszko, MD,a Gregory J. Schears, MD,b Afsaneh Pirzadeh, MD,c Joanna Kubin, MS,d
William J. Greeley, MD,c David F. Wilson, PhD,d and Anna Pastuszko, PhDdFrom th
ment
ment
Philad
of Pe
Funding
of He
Disclosu
Receive
public
Address
gery,
rchsd
0022-52
Copyrig
doi:10.1
1436Objective: The study objective was to investigate the effect of granulocyte-colony stimulating factor on the
expression of proteins that regulate apoptosis in newborn piglet brain after cardiopulmonary bypass and deep
hypothermic circulatory arrest.
Methods: The newborn piglets were assigned to 3 groups: (1) deep hypothermic circulatory arrest (30 minutes
of deep hypothermic circulatory arrest, 1 hour of low-flow cardiopulmonary bypass); (2) deep hypothermic cir-
culatory arrest with prior injection of granulocyte-colony stimulating factor (17 mg/kg 2 hours before cardiopul-
monary bypass); and (3) sham-operated. After 2 hours of post-bypass recovery, the frontal cortex, striatum, and
hippocampus were dissected. The expression of proteins was measured by gel electrophoresis or protein arrays.
Data are presented in arbitrary units. Statistical analysis was performed using 1-way analysis of variance.
Results: In the frontal cortex, only Fas ligand expression was significantly lower in the granulocyte-colony stim-
ulating factor group when compared with the deep hypothermic circulatory arrest group. In the hippocampus,
granulocyte-colony stimulating factor increased Bcl-2 (54.3  6.4 vs 32.3  2.2, P ¼ .001) and serine/
threonine-specific protein kinase (141.4 19 vs 95.9 21.1, P¼ .047) when compared with deep hypothermic
circulatory arrest group. Caspase-3, Bax, Fas, Fas ligand, death receptor 6, and Janus protein tyrosine kinase 2
levels were unchanged. The Bcl-2/Bax ratio was 0.33 for deep hypothermic circulatory arrest group and 0.93 for
the granulocyte-colony stimulating factor group (P¼ .02). In the striatum, when compared with the deep hypo-
thermic circulatory arrest group, the granulocyte-colony stimulating factor group had higher levels of Bcl-2
(50.3  7.4 vs 31.8  3.8, P ¼ .01), serine/threonine-specific protein kinase (132.7  12.3 vs 14  1.34,
P ¼ 2.3 3 106), and Janus protein tyrosine kinase 2 (126  17.4 vs 77.9  13.6, P ¼ .011), and lower levels
of caspase-3 (12.8  5.0 vs 32.2  11.5, P ¼ .033), Fas (390  31 vs 581  74, P ¼ .038), Fas ligand (20.5
 11.5 vs 57.8  15.6, P ¼ .04), and death receptor 6 (57.4  4.4 vs 108.8  13.4, P ¼ .007). The Bcl-2/
Bax ratio was 0.25 for deep hypothermic circulatory arrest and 0.44 for the granulocyte-colony stimulating fac-
tor groups (P ¼ .046).
Conclusions: In the piglet model of hypoxic brain injury, granulocyte-colony stimulating factor decreases proa-
poptotic signaling, particularly in the striatum. (J Thorac Cardiovasc Surg 2012;143:1436-42)Congenital heart disease (CHD) is the most common birth
defect, affecting 8 per 1000 live births. Many of these neo-
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The Journal of Thoracic and Cardiovascular Surand perioperative care, even the most complex surgical re-
pairs in this patient population are performed with low op-
erative mortality.
Better survival in infants and children with CHD requir-
ing surgical correction has led to a shift in focus to the long-
term outcomes, particularly neurodevelopmental progress
and quality of life. Recent studies have demonstrated neuro-
developmental dysfunction in patients with complex CHD.
The prevalence of this impaired neurologic function seems
to vary with the specific cardiac diagnosis.1,2 Long-term
follow-up studies in these children have revealed distinctive
patterns of neurodevelopmental dysfunction characterized
by cognitive impairment, impaired executive function, ex-
pressive speech and language abnormalities, impaired
visual-spatial and visual-motor skills, attention deficit/hy-
peractivity disorder, motor delays, and other learning
disabilities.3,4gery c June 2012
Abbreviations and Acronyms
CHD ¼ congenital heart disease
CPB ¼ cardiopulmonary bypass
DHCA ¼ deep hypothermic circulatory arrest
DR6 ¼ death receptor 6
Fas-L ¼ Fas ligand
G-CSF ¼ granulocyte-colony stimulating factor
LFCPB ¼ low-flow cardiopulmonary bypass
pAkt ¼ serine/threonine-specific protein kinase
pJAK2 ¼ Janus protein tyrosine kinase 2
SEM ¼ standard error of the mean
STAT ¼ signal transducer and activator of
transcription
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SMultiple causative factors for neurodevelopmental dys-
function in patients with complex CHD have been cited.5
Patient factors have included genetic abnormalities, con-
genital syndromes, and in utero and postnatal abnormal ce-
rebral blood flow patterns leading to an underdeveloped
central nervous system and microcephaly. Putative surgical
factors, such as deep hypothermic circulatory arrest
(DHCA) and low-flow cardiopulmonary bypass (LFCPB),
have been proposed.4 Early postoperative factors such as
low cardiac output, hypoxemia and hyperthermia also
may contribute. Genetic abnormalities and other patient
factors clearly cannot be altered. However, factors related
to DHCA, LFCPB execution, and early postoperative man-
agement are modifiable.
Advances in the treatment of cerebral injury associated
with hypoxic/ischemic insult depend on thorough under-
standing of the critical neuropathologic processes involved
in neuronal survival and death. Apoptosis, a programmed
cell death, seems to be the primary mechanism responsible
for cell death in the newborn brain. We have previously
used a piglet model of cardiopulmonary bypass (CPB) to de-
lineate the mechanisms of brain injury associated with pro-
longed DHCA and LFCPB.6 Marked alterations in
expression of selected proteins that play well-established
roles in regulation of apoptosis were observed, and we
have identified strategies that can limit this neuropathology.7
The goal of the present study was to determine whether
granulocyte-colony stimulating factor (G-CSF) may be an
effective neuroprotective agent, as tested in our CPB/
DHCAmodel of hypoxic cerebral injury. G-CSF, a member
of the cytokine family of growth factors, is a glycoprotein
broadly present within the central nervous system. G-CSF
exerts its effect via a specific receptor present on hemato-
poietic, neuronal, and glial cells. Numerous studies have re-
ported that ischemia upregulates the production of G-CSF
and its receptors. Exogenous administration of G-CSF has
been shown to be neuroprotective in a variety of strokeThe Journal of Thoracic and Carmodels.8-10 It has potent anti-inflammatory11 and anti-
excitatory properties.8 However, its most important func-
tion may be as a strong antiapoptotic factor.8,12,13
Available studies suggest that G-CSF is capable of
permeating the intact blood–brain barrier and is safe for
use in humans.8
We hypothesized that proapoptotic proteins increase and
antiapoptotic proteins decrease after CPB-DHCA and that
pretreatment of the piglets with G-CSF can suppress these
changes in signaling. To test these hypotheses, we have de-
termined the effect of G-CSF treatment on the expression of
selected regulatory proteins that play significant role in ei-
ther initiation (Bax, caspase-3, Fas, Fas ligand (Fas-L),
death receptor 6 [DR6]) or inhibition (Bcl-2, serine/
threonine-specific protein kinase [pAkt], and Janus protein
tyrosine kinase 2 [pJAK2]) of apoptotic signaling.MATERIALS AND METHODS
Animal Model
Eighteen newborn piglets, 3 to 5 days old (2.0–3.0 kg), were anesthe-
tized with 4% isoflurane (Novaplus, Hospira Inc, Lake Forest, Ill). Pulse
oximetry, electrocardiogram, and temperature measurements were begun
immediately after induction of anesthesia. A 1.5% lidocaine-HCl was
used as a local anesthetic. After tracheotomy, pancuronium (1.5 mg/kg)
was used for neuromuscular blockade to allow mechanical ventilation.
Fentanyl-citrate (30 mg/kg) was injected intravenously, and the animals
were mechanically ventilated with a mixture of oxygen (FIO2 21%) and
0.5% isoflurane. The femoral artery and veinwere then cannulated, and an-
esthesia was maintained with 0.5% isoflurane and boluses of pancuronium
(1 mg/kg/h). After a 2-hour period, CPBwas initiated. After bypass, the an-
imals were recovered for 2 hours under anesthesia and then euthanized with
saturated KCl.
All animal procedures were in strict accordance with the National Insti-
tutes of Health ‘‘Guide for the Care and Use of Laboratory Animals: and
have been approved by the local Animal Care and Use Committee.
Cardiopulmonary Bypass Technique
The circuit was primed with Plasma-Lyte A (Baxter Healthcare Corp,
Deerfield, Ill) and 25% albumin. Donor whole blood was then added to
maintain a hematocrit of 25% to 30%. Heparin (1000 units), fentanyl
(50 mg), pancuronium (1 mg), CaCl2 (500 mg), methylprednisolone (60
mg), cefazolin (100 mg), furosemide (2 mg), and NaHCO3 (25 meq)
were then added to the pump prime. A membrane oxygenator (Lilliput;
COBE Cardiovascular, Inc, Arvada, Colo), a roller pump system
(COBE), and an arterial filter (Capiox; Terumo Cardiovascular Systems,
Corp, Ann Arbor, Mich) were used. A median sternotomy was performed,
and after 500 units of heparin were administered intravenously, the ascend-
ing aorta and the right atrial appendagewere cannulated. Full CPB flow rate
was set at 150 mL/kg/min. The pH-stat blood gas management was main-
tained in all experiments.
After cooling to 18C, the piglets were introduced to 30 minutes of
DHCA followed by 1 hour of LFCPB at 20 mL/kg/min. All animals
were then rewarmed for 30minutes at full flow (150mL/kg/min), separated
from CPB and recovered for 120 minutes under anesthesia, and finally eu-
thanized with saturated KCl. The control animals did not undergo CPB but
were anesthetized and underwent a sham operation. After euthanasia, the
frontal cortex, striatum, and hippocampus were immediately dissected
from the brain and frozen at80C for later analysis.
The animals were randomly assigned to 1 of 3 groups: 1) CPB with cir-
culatory arrest (n ¼ 6, DHCA group), 2) DHCA with prior injection ofdiovascular Surgery c Volume 143, Number 6 1437
FIGURE 1. Effect of DHCA and G-CSF on Bax, Fas-L, and DR6 immunoreactivities in the frontal cortex of newborn brain. Bars represent the means 
standard error of the mean (SEM) for the density of the bands for 6 independent experiments.
TABLE 1. Effect of granulocyte-colony stimulating factor on Bcl-2/
Bax ratio in the brain of newborn piglets after cardiopulmonary
bypass–deep hypothermic circulatory arrest
Region of brain Control DHCA G-CSF
Frontal cortex 0.96  0.14 0.80  0.06 0.58  0.09
P ¼ .043*
Hippocampus 0.80  0.06 0.33  0.04
P ¼ .00001*
0.93  0.21
P ¼ .02y
Striatum 0.49  0.05 0.25  0.02
P ¼ .02*
0.44  0.08
P ¼ .046y
Results are means  SEM for 6 experiments. *P value compared with control. yP
value compared with DHCA group.
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SG-CSF at a concentration of 17 mg/kg (n¼ 6, G-CSF group), and 3) sham-
operated (n ¼ 6). The G-CSF was given by intravenous injection 2 hours
before the beginning of bypass.
Protein Expressions
For the Western blotting, the samples of frozen tissue were homoge-
nized, prepared, and incubated with specific antibodies as described previ-
ously.6,7 Expression of caspase-3, Fas, Fas-L, and DR6 were determined by
RayBioTech, Inc (Norcross, Ga) using the protein array method.
Data Analysis
Autoradiographic films were analyzed using Scion Image software (Na-
tional Institutes of Health, Bethesda, Md). Each blot contained 3 sets of
samples, 2 experimental groups, and the control group. The measurements
of individual proteins are presented as the means  standard error of the
mean for 6 experiments. The data within each brain region (3 groups)
were tested for significance by 1-way analysis of variance, and the P value
for comparisons between the groups was calculated using the 2-tailed un-
paired t test. The Bonferroni correction for multiple comparisons would at-
tribute significance at the 95% tile for P values of .017 and marginal
significance for P values between .05 and .017. Our hypotheses were tested
by binary analysis of probability of observing the measured direction of the
changes in protein levels with the null hypothesis of an equal probability of
increase or decrease.
RESULTS
In 3 regions of the newborn piglet brain, the immunore-
activity of antiapoptotic Bcl-2, p-Akt, and p-JAK2, and
proapoptotic Bax, caspase-3, Fas, Fas-L, and DR6 proteins
were determined. Only the proteins that are significantly
different between experimental groups are shown in
Figures 1 through 4.
Frontal Cortex
Bcl-2 was not significantly different among the experi-
mental groups of animals. Bax increased from the control
value of 58.3  13.6 to 102  8.2 (P ¼ .002) in the
DHCA group and was significantly higher in the G-CSF
group (Figure 1). The Bcl-2/Bax ratios were 0.96  0.14
(control), 0.80  0.06 (DHCA), and 0.58  0.09 (G-CSF)
(Table 1). pAkt, pJAK2, and Fas were not significantly dif-
ferent among the experimental groups. DR6 increased from
control of 76  5.3 to 110  8.9 (P ¼ .016) for DHCA, but1438 The Journal of Thoracic and Cardiovascular Surthere was no significant difference between DHCA and
G-CSF. Fas-L slightly increased in DHCA versus control
(34  13.9 vs 57.6  8.8) and decreased significantly
with G-CSF versus DHCA (57.6  8.8 vs 27  3.5,
P ¼ .012). The caspase-3 level was too low to measure in
all experimental groups.Hippocampus
Bcl-2 was lower in the DHCA group versus control (32.3
 2.16 vs 87.2  22, P ¼ .005) and increased significantly
in the G-CSF group (to 54.3  6.4, P ¼ .001) (Figure 2).
The calculated Bcl-2/Bax ratios were 0.8  0.06 (control),
0.33 0.04, P¼ .00001 (DHCA), and 0.93 0.21, P¼ .02
(G-SCF) (Table 1).
The pAkt was not significantly different between the con-
trol (75  13.9) and DHCA (95.9  21.1) groups. In the
G-CSF group, pAkt increased to 141.4  19.4 compared
with both the DHCA (P ¼ .047) and control (P ¼ .003)
groups (Figure 2). pJAK2, caspase-3, Fas, Fas-L, and
DR6 were similar in all 3 groups.Striatum
Bcl-2 decreased in the DHCA group compared with con-
trol (31.8 3.8 vs 59.9 7.2, P¼ .0009) and increased sig-
nificantly in the G-CSF group compared with the DHCA
group (50.3  7.4 vs 31.8 3.8, P ¼ .01) (Figure 3). Theregery c June 2012
FIGURE 2. Effect of DHCA and G-CSF on Bcl-2, pAkt, and pJAK2 immunoreactivities in the hippocampus of newborn brain. Bars represent the means
SEM for the density of the bands for 6 independent experiments.
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lated Bcl-2 to Bax ratios were 0.49  0.05 for the control
group, 0.25  0.02 (P ¼ .02) for the DHCA group, and
0.44  0.08 (P ¼ .046 compared with DHCA) for the
G-CSF group (Table 1). pAkt was 60.4 11.5 in the control
group and decreased to 14  1.34 in the DHCA group
(P¼ .0003). In the G-CSF group, pAkt was significantly in-
creased (to 132.7  12.3) compared with both the DHCA
(P ¼ 2.3x106) and control (P ¼ .0005) groups (Figure 3).
The pJAK2 level was similar in the control (75.6  17.4)
and DHCA (77.9  13.6) groups but was increased in the
G-CSF group when compared with both control
(P ¼ .015) and DHCA (P ¼ .011) groups (Figure 3).
The caspase-3 level was low in the control group (2.4 
1.7) and increased marginally in the DHCA group to 32.5
11.5 (P ¼ .033). In the G-CSF group, the mean value for
caspase-3 was lower (12.8  5.0) than in the DHCA group
(Figure 4), but the variability was great enough that the dif-
ference was not statistically significant.
Fas level was slightly higher in DHCA (581  74) than
control (425  61) and marginally lower than control in
the G-CSF group (390  31, P ¼ .038) (Figure 4). Fas-L
was 19.1  9.1 in the control group and increased to
57.815.6 (P ¼ .058) in the DHCA group. Fas-L was mar-
ginally lower in the G-CSF group compared with the DHCA
group (20.5  11.1, P ¼ .04) (Figure 4). DR6 was 61.6 
14.8 in the control group and marginally increased to
108.8 13.4 (P¼ .046) in the DHCA group and decreasedFIGURE 3. Effect of DHCA andG-CSF on Bcl-2, pAkt, and pJAK2 immunore
for the density of the bands for 6 independent experiments.
The Journal of Thoracic and Carin the G-CSF group (57.4  4.4, P ¼ .007) compared with
the DHCA group (Figure 4).
DISCUSSION
The purpose of this study was to determine whether pre-
treatment with G-CSF decreases proapoptotic signaling in
the newborn brain in a hypoxia/ischemia model of CPB
and DHCA. To achieve this, changes in phosphorylation
and expression of selected proteins in the brain of newborn
piglets were measured. All investigated proteins have well-
established roles in the regulation of apoptotic activity.
There are 2 primary reasons for focusing on apoptotic ac-
tivity. First, several studies shown that apoptosis, rather than
necrosis, is the predominant mechanism involved in cell
death in the neonatal brain. Second, apoptotic processes
are activated within hours of reperfusion, whereas necrosis
can be detected only after longer recovery times.
A newborn piglet model was chosen to take advantage
of the similar stage of development of the brain and sim-
ilar size to the human newborn. The CPB-DHCA protocol
used in our study was 30 minutes of DHCA followed by
60 minutes of low flow at 20 mL/kg/min. The protocol
was selected on the basis of our extensive experience
with evaluating apoptotic activity associated with different
circulatory arrest periods and low flow rates. The protocol
was shown to result in activation of apoptotic signaling
that was large enough to be easily measured and
reproduced.activities in the striatum of newborn brain. Bars represent the means SEM
diovascular Surgery c Volume 143, Number 6 1439
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FIGURE 4. Effect of DHCA and G-CSF on caspase-3, Fas, Fas-L, and DR6 immunoreactivities in striatum of newborn brain. Bars represent the means
SEM for the density of the bands for 6 independent experiments.
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SThis study demonstrates that CPB-DHCA increases proa-
poptotic signaling particularly in striatumof newborn piglets.
The administration of G-CSF before DHCA diminishes this
proapoptotic signaling and increases antiapoptotic signaling
in this region of the newborn brain, as demonstrated by
decreased expression of caspase-3, Fas, Fas-L, and DR6,
and increased expression ofBcl-2, pAkt, and pJAK2proteins.
DHCA did not significantly change most of the proteins
in the frontal cortex and hippocampus. Only Bax and DR6
levels were elevated in the cortex and Bcl-2 level decreased
in the hippocampus. In the hippocampus, treatment with
G-CSF resulted in increased expression of pAkt and Bcl-2,
whereas in the frontal cortex it lead to decreased expression
of Fas-L and increased expression of Bax.
Fas, Fas-L, DR6, and caspase-3 are the proapoptotic pro-
teins. Fas is a member of the tumor necrosis factor receptor
family of cell surface death receptors that mediates apopto-
tic signals on binding to its specific ligand, Fas-L. Ligation
of Fas to Fas-L results in formation of the death-inducing
signaling complex and activation of the proteolytic caspase
cascade.14 Fas plays an important role in parenchymal cell
apoptosis in many organs during tissue injury and inflam-
matory infiltration of lymphocytes.
Another member of the tumor necrosis factor receptor
family that can induce apoptosis is DR6. DR6 is broadly ex-
pressed by developing neurons and is required for normal
cell body death and axonal pruning both in vivo and after
trophic-factor deprivation in vitro. DR6 can induce apopto-
sis by triggering caspases activation and degeneration of
both neuronal cell bodies (via Bax and caspase-3) and axons
(via caspase-6).1440 The Journal of Thoracic and Cardiovascular SurCaspase-3 plays a vital role in the induction, transduc-
tion, amplification, and execution of apoptotic signals
within the cell. Caspase-3 is activated in different
hypoxia-ischemiamodels, and its inhibition has been shown
to have neuroprotective effects in both adult and neonatal
brains.15 In the striatum, there was a significant increase
of caspase-3 in the DHCA group and a clear trend toward
decreased expression of this protein in the G-CSF group.
G-CSF also has an effect on Bcl-2 and Bax, 2 members of
Bcl-2 family of proteins that can play a substantial role in
regulating cell death by apoptosis.16,17 They can promote
cell survival (Bcl-2) or cell death (Bax). Several studies
have shown that Bax plays a critical role in hypoxic/
ischemic injury, and its deficiency has protective effect in
hypoxic brain damage. In response to hypoxia or
ischemia, Bax undergoes a conformational change and
leads to activation of the caspase cascade. Bcl-2, an antia-
poptotic protein of the Bcl-2 family, can prevent this confor-
mational change in Bax. There is evidence that
overexpression of Bcl-2 protects against apoptosis and is-
chemic neuronal death. Bcl-2 can diminish the Fas-
mediated apoptosis.
The increase in expression of Bcl-2 in the striatum and
hippocampus in G-CSF–treated animals in our study sug-
gests that an important mechanism of protection by
G-SCF can be through increase in the level of Bcl-2. Increased
Bcl-2 as one protective mechanism of G-CSF was proposed
also by Cao and colleagues.18 They examined the effect
of G-CSF on dopaminergic neurons in a mouse model of
Parkinson disease and reported that G-CSF significantly de-
creased the loss of tyrosine hydroxylase-positive neuronsgery c June 2012
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Sand increased the Bcl-2 level. The active form of Bcl-2 can
heterodimerize with Bax, and their ratio correlates with the
cellular susceptibility to apoptotic stimuli. An increased
Bax/Bcl-2 ratio occurs in piglets after hypoxic insult, which
is consistent with increased susceptibility to apoptosis in the
hypoxic newborn brain.16
The present study shows that in both striatum and hippo-
campus, the Bcl-2/Bax ratios after DHCA were approxi-
mately half of those in sham-operated animals. These
findings are in agreement with the report by Zhang and col-
leagues17 that the Bax/Bcl-2 ratio increased after CPB in the
hippocampus in a rat model of hypothermic CPB with
hemodilution.
Injecting G-CSF before bypass nearly completely abol-
ished the DHCA-dependent decrease of the Bcl-2/Bax ratio
in the hippocampus and striatum, consistent with a protec-
tive effect of G-CSF against apoptotic damage. This is sim-
ilar to the data of Solaroglu and colleagues,12 who reported
that in a rat ischemia model using middle cerebral artery oc-
clusion, G-CSF increased Bcl-2 expression and decreased
Bax translocation to mitochondria.
The antiapoptotic action of G-CSF also can occur
through activation of the neuronal PI3K/Akt pathway.8
This is also one of possible mechanisms of G-CSF protec-
tion observed in our study. The pAkt levels decreased in
the striatum and remained unchanged in the hippocampus
after DHCA when compared with sham-operated animals.
In the animals treated with G-CSF, however, pAkt increased
in both brain regions compared with sham-operated or
DHCA animals. Akt is an important antiapoptotic protein
that helps to control the balance between cell survival and
cell death via several mechanisms. For example, Bad, an-
other proapoptotic member of the Bcl-2 family, in its un-
phosphorylated form can bind to Bcl-XL (antiapoptotic
protein) and thus block cell survival. Activation of Akt in-
duces Bad phosphorylation and inhibits its proapoptotic
activity.
The region of the brain with the greatest increase of pAkt
in response to G-CSF treatment was the striatum. This re-
gion also showed significant increase of JAK2. JAKs are
able to phosphorylate the signal transducer and activator
of transcription (STAT) protein family after stimulation of
several different membrane receptors. In a focal cerebral is-
chemia rat model, STAT3 expression in the penumbra of the
infarction has been shown to be increased after G-CSF treat-
ment.9 Komine-Kobayashi and colleagues19 reported that
activation of the JAK2/STAT3 pathway by G-CSF activates
Bcl-2 protein after transient focal cerebral ischemia inmice,
thus decreasing apoptotic cell death.
As we have described, the evidence for a protective effect
of G-CSF was particularly strong in the striatum, one of the
regions of the brain that is most vulnerable to hypoxia/is-
chemia–induced injury. In the striatum, its protective effect
was manifested by an increase of Bcl-2, Bcl-2/Bax ratio,The Journal of Thoracic and CarpAkt, and pJAK-2, and a decrease of caspase-3, Fas, Fas-L,
and DR6 compared with DHCA alone. G-SCF can also
protect dopaminergic neurons via other pathways.20
Several studies have shown that hypoxic/ischemic brain
injury results in a characteristic pattern of damage in the
striatum, with the evidence for both apoptotic and necrotic
cell death detected in the brains of newborn piglets21 and
immature rats.22
Striatum, caudate putamen, and nucleus accumbens re-
gions of the brain are the most important subcortical struc-
tures in the motor circuit and the main input sites for the
basal ganglia. This area has been implicated in movement
control and plays a critical role in memory function. Chil-
dren who underwent heart surgery with CPB and DHCA
as neonates or infants show distinctive patterns of neuro-
logic disturbance. Neurocognitive dysfunction after CPB
impairment has been well documented.23 The incidence
of cognitive dysfunction immediately after cardiac surgery
is reported in the range of 20% to 80%, with many patients
experiencing long-term or permanent residual deficits24,25
consistent with significant long-term injury to the striatum
and hippocampus.CONCLUSIONS
In a newborn piglet CPB/DHCA model, administration
of G-CSF before DHCA decreases proapoptotic signaling
activity particularly in the striatum and to a lesser degree
in the hippocampus, 2 regions of the brain particularly
prone to injury in hypoxic/ischemic insult. As hypothe-
sized, in the striatum, 7 of the 8 proteins increased or de-
creased (5 significantly) after DHCA (DHCA compared
with control) and all 8 (6 significantly) of the proteins in-
creased or decreased in the G-CSF–treated piglets com-
pared with those without G-CSF treatment. Our results
are consistent with the hypothesis that G-CSF may be an
important neuroprotective agent, leading to improve out-
comes in high-risk neonates requiring surgical repair for
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